Tekla Ev To Operating Cash Flow vs Price To Sales Ratio Analysis
| HQH Stock | USD 18.48 0.25 1.33% |
Tekla Healthcare financial indicator trend analysis is much more than just breaking down Tekla Healthcare Inv prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tekla Healthcare Inv is a good investment. Please check the relationship between Tekla Healthcare Ev To Operating Cash Flow and its Price To Sales Ratio accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Healthcare Investors. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.
Ev To Operating Cash Flow vs Price To Sales Ratio
Ev To Operating Cash Flow vs Price To Sales Ratio Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tekla Healthcare Inv Ev To Operating Cash Flow account and Price To Sales Ratio. At this time, the significance of the direction appears to have strong relationship.
The correlation between Tekla Healthcare's Ev To Operating Cash Flow and Price To Sales Ratio is 0.66. Overlapping area represents the amount of variation of Ev To Operating Cash Flow that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Tekla Healthcare Investors, assuming nothing else is changed. The correlation between historical values of Tekla Healthcare's Ev To Operating Cash Flow and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Operating Cash Flow of Tekla Healthcare Investors are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Ev To Operating Cash Flow i.e., Tekla Healthcare's Ev To Operating Cash Flow and Price To Sales Ratio go up and down completely randomly.
Correlation Coefficient | 0.66 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Ev To Operating Cash Flow
A valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows.Price To Sales Ratio
Price to Sales Ratio is figured by comparing Tekla Healthcare Inv stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Tekla Healthcare sales, a figure that is much harder to manipulate than other Tekla Healthcare Investors multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Most indicators from Tekla Healthcare's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tekla Healthcare Inv current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Healthcare Investors. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. As of now, Tekla Healthcare's Selling General Administrative is decreasing as compared to previous years. The Tekla Healthcare's current Enterprise Value Over EBITDA is estimated to increase to 16.14, while Sales General And Administrative To Revenue is projected to decrease to 0.02.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 2.0M | 1.8M | 2.1M | 1.9M | Cost Of Revenue | 11.3M | 10.9M | 12.5M | 7.3M |
Tekla Healthcare fundamental ratios Correlations
Click cells to compare fundamentals
Tekla Healthcare Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tekla Healthcare fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 1.1B | 1.2B | 926.3M | 932.5M | 1.1B | 673.0M | |
| Other Current Liab | (31.4K) | 4.3M | 1.2M | 1.1M | 1.0M | 982.1K | |
| Total Current Liabilities | 31.4K | 15.6M | 9.7M | 1.1M | 1.3M | 1.3M | |
| Total Stockholder Equity | 1.1B | 1.2B | 916.6M | 931.3M | 1.1B | 667.3M | |
| Net Debt | 2.5M | 11.3M | 8.5M | (214.0) | (246.1) | (233.79) | |
| Cash | (2.5M) | 935.0 | 792.0 | 214.0 | 192.6 | 182.97 | |
| Non Current Assets Total | 1.1B | 1.2B | 923.4M | 925.6M | 1.1B | 686.0M | |
| Non Currrent Assets Other | (1.1B) | (1.2B) | (923.4M) | (925.6M) | (833.0M) | (874.7M) | |
| Other Assets | 264.1K | 66.1K | 49.4K | 51.1K | 46.0K | 43.7K | |
| Cash And Short Term Investments | 2.5M | 935.0 | 792.0 | 214.0 | 246.1 | 233.8 | |
| Common Stock Shares Outstanding | 43.9M | 44.5M | 47.3M | 49.4M | 56.9M | 30.4M | |
| Liabilities And Stockholders Equity | 1.1B | 1.2B | 926.3M | 932.5M | 1.1B | 673.0M | |
| Total Liab | 1.1M | 15.6M | 9.7M | 1.1M | 1.3M | 1.3M | |
| Total Current Assets | 4.1M | 4.0M | 2.9M | 6.9M | 7.9M | 8.3M | |
| Common Stock | 438.7K | 454.3K | 473.4K | 494.4K | 568.6K | 540.2K | |
| Net Receivables | 4.1M | 4.0M | 2.9M | 6.9M | 7.9M | 8.3M | |
| Net Tangible Assets | 870.8M | 1.1B | 1.2B | 916.6M | 1.1B | 962.8M | |
| Retained Earnings | 239.5M | 303.1M | 24.8M | 6.0M | 5.4M | 5.1M | |
| Long Term Investments | 1.1B | 1.2B | 923.4M | 925.6M | 1.1B | 954.8M | |
| Other Current Assets | (6.6M) | (23.7M) | (51.2M) | (39.6M) | (35.6M) | (33.9M) | |
| Capital Stock | 438.7K | 454.3K | 473.4K | 494.4K | 445.0K | 422.7K | |
| Short Term Investments | 2.5M | 19.6M | 48.3M | 32.7M | 37.6M | 26.2M | |
| Non Current Liabilities Total | 1.1M | 15.6M | 9.7M | 1.1M | 1.0M | 982.1K |
Currently Active Assets on Macroaxis
When determining whether Tekla Healthcare Inv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tekla Healthcare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tekla Healthcare Investors Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tekla Healthcare Investors Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Healthcare Investors. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Healthcare. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.145 | Dividend Share 1.66 | Earnings Share 1.31 | Revenue Per Share 0.197 | Quarterly Revenue Growth (0.06) |
The market value of Tekla Healthcare Inv is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Tekla Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Healthcare's market value can be influenced by many factors that don't directly affect Tekla Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.